首页|含伏诺拉生四联疗法根除幽门螺杆菌感染的疗效

含伏诺拉生四联疗法根除幽门螺杆菌感染的疗效

扫码查看
目的 观察含伏诺拉生的四联14d疗法治疗幽门螺杆菌(Hp)感染的效果。方法 回顾性分析120例Hp阳性患者,将其按治疗方案分为治疗组和对照组,各60例。治疗组口服伏诺拉生20 mg+枸橼酸铋钾220 mg+阿莫西林1 000 mg+呋喃唑酮100 mg;对照组口服奥美拉唑20 mg+阿莫西林1 000 mg+枸橼酸铋钾220 mg+呋喃唑酮100 mg,均每日2次,共14d。患者均在疗程结束后4~6周内行14C-尿素呼气试验,分别观察2组Hp根除情况及不良反应的发生情况。结果 纳入的120例患者中,男性57例,女性63例,年龄20~69岁,平均(37。9±5。4)岁,Hp根除率治疗组高于对照组(97%vs。80%,P<0。05)。2组不良反应发生率无显著差异(P>0。05)。结论 含伏诺拉生的四联14 d疗法治疗Hp感染是一种安全高效的根除Hp治疗方法,可作为一线及二线治疗方案。
Effect of quadruple therapy with vonoprazan on eradication of Helicobacter pylori infection
AIM To observe the effect of vonoprazan quadruple 14-day therapy on Helicobacter pylori(Hp)infection.METHODS A total of 120 Hp positive patients were included and divided into treatment group and control group,60 cases in each group.The treatment group was given vonoprazan 20 mg+bismuth potassium citrate 220 mg+amoxicillin 1 000 mg+furazoldone 100 mg,and the control group was given omeprazole 20 mg+amoxicillin 1 000 mg+bismuth potassium citrate 220 mg+furazoldone 100 mg,twice a day for 14 days.The 14C-urea breath test was performed in all patients 4 to 6 weeks after the course of treatment,and the eradication rate of Hp and the occurrence of adverse reactions in the two groups were observed respectively.RESULTS Among the 120 patients included,there were 57 males and 63 females,aged from 20 to 69 years old,with an average age of(37.9±5.4)years.The Hp eradication rate in the treatment group was higher than that in the control group(97%vs.80%,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).CONCLUSION Quadruple 14-day therapy with vonoprazan is a safe and highly effective treatment for Hp eradication and can be used as a first-and second-line treatment.

vonoprazanquadruple therapyHelicobacter pylori

钟万锷、曹萍

展开 >

宁波市第六医院消化内科,浙江宁波 315040

伏诺拉生 四联疗法 幽门螺杆菌

2024

中国新药与临床杂志
中国药学会 上海市食品药品监督管理局科技情报研究所

中国新药与临床杂志

CSTPCD北大核心
影响因子:0.967
ISSN:1007-7669
年,卷(期):2024.43(3)
  • 16